Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Bristol Myers Squibb (BMY)

Bristol Myers Squibb Reports Q3 2026 Results and Raises Full-Year Revenue Guidance

Positive Impact 4 of 5 earnings

Bristol Myers Squibb reported third-quarter 2026 total revenues of $13.1 billion, representing a 7% increase compared to the same period in 2025. The company raised its full-year 2026 revenue guidance range to $49.75 billion to $50.25 billion, driven by momentum in its Growth Portfolio.

Key points

  • Third-quarter total revenues increased 7% to $13.1 billion compared to $12.2 billion in 2025.
  • GAAP EPS was $1.05 and non-GAAP EPS was $1.35 for the third quarter of 2026.
  • Full-year 2026 revenue guidance was raised to a range of $49.75 billion to $50.25 billion.
  • Non-GAAP EPS guidance for 2026 was updated to a range of $6.35 to $6.55.

The filing

CompanyBristol Myers Squibb (BMY)
Form8-K, current report
Filed with the SECOct 29, 2026, 7:05 AM ET
Accession number0000014272-26-000022

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Oct 29, 2026, 7:17 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.